A 66-year-old man presented in our Department having suffered, in the last five years, from the onset and progressive worsening of exertional dyspnoea.
The patient was not following any pharmacological therapy at the time of the first visit. At clinical evaluation, the patient was eupneic and apyretic; blood pressure was 120/80 mmHg and heart rate was 68 beats/min; height was 160 cm, weight was 57 Kg and BMI was 22.3. Chest physical examination showed a significant reduction in physiological lung sounds with bilateral diffuse expiratory wheezing. Baseline pulmonary function tests (PFTs) showed a very severe bronchial obstruction: forced expiratory volume in the first second (FEV 1 ) was 0.62 L (25% of predicted), FEV 1 /FVC (forced vital capacity) was 59%; FEV 1 recorded after the bronchial reversibility test (salbutamol 400 mg) increased by 23% (30% of predicted). Oxygen saturation was 99%. Chest X-rays showed an increased bronchovascular marking in the absence of pleuroparenchymal lesions.
The patient was therefore prescribed the following drugs as inhalers: tiotropium 18 μg once daily and salmeterol/fluticasone 50/500 μg twice daily. Furthermore, the patient was advised to undergo a cardiovascular screening (echocardiography, Holter and stress electrocardiogram) and a follow-up visit was scheduled after 3 months.
At the new clinical evaluation, the patient referred the persistence of exertional dyspnoea and the occurrence of a second acute disease exacerbation with high fever and productive cough, treated with oral antibiotics. PFT showed only a slight improvement of lung function: FVC 1.33 L (42% of predicted), FEV 1 0.73 L (29% of predicted), FEV 1 /FVC 54%; post-bronchodilator FEV 1 increased by 19% (34.1% predicted). Oxygen saturation was 97%. Chest physical examination did not change compared to the previous one, a part from the presence at rest of sporadic isolated monomorphic ventricular premature beats in the presence of a normal echocardiography.
The persistence of symptoms and wheezing, as well as evidence of recurring exacerbations showed an unsatisfactory disease control. Moreover, the high increase in postbronchodilator FEV 1 (+23% and +19%) suggested a status of ongoing bronchosphasm It was therefore decided to add roflumilast 500 μg once daily to the previously prescribed treatment [2] . The patient, in fact, completely fulfilled both clinical and functional criteria requested to be administered roflumilast: severe COPD phenotype (FEV 1 post-bronchodilator <50%), symptoms not under control and history of frequent exacerbations (>2/year). The patient was therefore listed in the Italian Drug Agency monitoring register [3] .
On subsequent clinical evaluations, the patient showed a significant improvement in respiratory symptoms with a consistent reduction of exertional dyspnoea and no significant side effects. No weight loss was recorded, although a more frequent alvus was reported. In view of the above clinical benefits and of the lack of serious adverse events, it was decided to continue roflumilast 500 μg once daily as add-on therapy. After three months of treatment with roflumilast the therapeutic plan was renewed in accordance with requirements set by the Italian Drug Agency [3] .
After six months of roflumilast therapy, respiratory symptoms were progressively improving and no exacerbations occurred. At the chest physical examination no adjunct pathological sounds were present any more. Pulmonary function tests were further improved: FVC 1.88 L (60% of predicted), FEV 1 1.02 L (41% of predicted).
Twelve months after his first clinical evaluation the patient was re-evaluated. Respiratory symptoms appeared to be completely under control and no exacerbations occurred since the previous visit. Body weight was still stable and alvus frequency was now regular. Chest physical examination revealed no pathological sounds. Oxygen saturation was 98%. PFT showed a further improvement in lung function (FVC 64%, FEV 1 49%).
Discussion
Interestingly, on top of the widely reported positive effects on respiratory symptoms [4] , our patient showed a progressive significant improvement in lung function during the roflumilast treatment period. Baseline FEV 1 almost doubled over a 12-month treatment period, from 25% to 49%. Similarly, FVC increased up to 64%. A further important outcome was represented by the complete absence of exacerbations, since beginning of roflumilast therapy [5] . Moreover, except for a transient change in the alvus frequency, no adverse events were experienced [4, 6] .
In conclusion, this one-year follow-up case report shows that roflumilast represents a safe and effective therapeutic strategy in severe COPD patients, not only for managing clinical symptoms and exacerbation rates, as already consistently reported, but also for significantly improving lung function parameters. 
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